Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 3 Study of LOXO-305 in CLL/SLL Patients

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Disease Types: Leukemia

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

For more information:

https://clinicaltrials.gov/ct2/show/NCT04666038?term=A+Phase+3+Open-Label%2C+Randomized+Study+of+LOXO-305+versus+Investigator%27s+Choice+of+Idelalisib+plus+Rituximab+or+Bendamustine+plus+Rituximab+in+BTK+Inhibitor+Pretreated+Chronic+Lymphocytic+Leukemia%2FSmall+Lymphocytic+Lymphoma&draw=2&rank=1